Form 4: AN2 Therapeutics COO Sells Shares for Tax Obligations

AN2 Therapeutics' Chief Operating Officer, Joshua M. Eizen, sold 2,819 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Joshua M. Eizen, Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics, Inc., sold 2,819 shares of common stock on November 4, 2025.
• The shares were sold at a price of $1.14 per share.
• The sale was conducted to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on the same date.
• Following this transaction, Mr. Eizen beneficially owns 177,353 shares of common stock.
• This total includes 31,500 RSUs vesting 1/4th annually over four years from November 4, 2024.
• It also includes 22,500 RSUs vesting 1/3rd annually over three years from January 1, 2025.
• Additionally, 45,000 RSUs are included, with 2/3rd vesting on January 1, 2026, and 1/3rd vesting on July 1, 2026.
• The adjusted total beneficial ownership also reflects the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2025.

Sentiment

Score: 6

Explanation: The sale of shares is for tax purposes, a neutral event. However, the concurrent purchase of shares via an ESPP and the significant remaining unvested RSUs suggest continued insider confidence and long-term alignment, leading to a slightly positive sentiment.

Positives

• The reporting person purchased 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2025, indicating continued confidence in the company.
• Significant RSU grants (totaling 99,000 RSUs) are still outstanding and vesting, aligning management's interests with long-term shareholder value.

Negatives

• The sale of 2,819 shares, even for tax purposes, represents a reduction in direct beneficial ownership.

Future Outlook

The reporting person has substantial unvested Restricted Stock Units (RSUs) with vesting schedules extending through at least July 1, 2026, indicating a long-term incentive structure tied to future company performance.

Industry Context

This filing is a routine insider transaction (Form 4) and does not provide broader industry context. It reflects an individual officer's equity compensation management rather than company-wide strategic or operational updates.

Stakeholder Impact

• Shareholders: The sale for tax purposes is a routine event and unlikely to significantly impact shareholders. The ESPP purchase and ongoing RSU vesting demonstrate continued insider alignment with shareholder interests.
• Employees: The existence of an Employee Stock Purchase Plan (ESPP) and Restricted Stock Units (RSUs) indicates standard equity compensation programs are in place.

Next Steps

• Continued vesting of 31,500 RSUs annually over four years from November 4, 2024.
• Continued vesting of 22,500 RSUs annually over three years from January 1, 2025.
• Vesting of 2/3rd of 45,000 RSUs on January 1, 2026.
• Vesting of 1/3rd of 45,000 RSUs on July 1, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where an officer sold shares to cover tax obligations from RSU vesting and also purchased shares through an ESPP. Such transactions are common and generally do not signal a change in the company's fundamental outlook or the officer's confidence. The significant remaining unvested RSUs further suggest long-term alignment. Therefore, based solely on this filing, a "hold" recommendation is appropriate as there's no new information to warrant a change in investment thesis.

Keywords

AN2 Therapeutics, ANTX, Form 4, Insider Trading, Stock Sale, RSU Vesting, Tax Withholding, Employee Stock Purchase Plan, Joshua M. Eizen, Officer Transaction